Literature DB >> 19933796

Antimicrobial peptide hLF1-11 directs granulocyte-macrophage colony-stimulating factor-driven monocyte differentiation toward macrophages with enhanced recognition and clearance of pathogens.

Anne M van der Does1, Sylvia J P Bogaards, Bep Ravensbergen, Henry Beekhuizen, Jaap T van Dissel, Peter H Nibbering.   

Abstract

The human lactoferrin-derived peptide hLF1-11 displays antimicrobial activities in vitro and is effective against infections with antibiotic-resistant bacteria and fluconazole-resistant Candida albicans in animals. However, the mechanisms underlying these activities remain largely unclear. Since hLF1-11 is ineffective in vitro at physiological salt concentrations, we suggested modulation of the immune system as an additional mechanism of action of the peptide. We investigated whether hLF1-11 affects human monocyte-macrophage differentiation and determined the antimicrobial activities of the resulting macrophages. Monocytes were cultured for 7 days with GM-CSF in the presence of hLF1-11, control peptide, or saline for various intervals. At day 6, the cells were stimulated with lipopolysaccharide (LPS), lipoteichoic acid (LTA), or heat-killed C. albicans for 24 h. Thereafter, the levels of cytokines in the culture supernatants, the expression of pathogen recognition receptors, and the antimicrobial activities of these macrophages were determined. The results showed that a short exposure of monocytes to hLF1-11 during GM-CSF-driven differentiation is sufficient to direct differentiation of monocytes toward a macrophage subset characterized by both pro- and anti-inflammatory cytokine production and increased responsiveness to microbial structures. Moreover, these macrophages are highly effective against C. albicans and Staphylococcus aureus. In conclusion, hLF1-11 directs GM-CSF-driven differentiation of monocytes toward macrophages with enhanced effector functions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19933796      PMCID: PMC2812139          DOI: 10.1128/AAC.00652-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Antimicrobial peptides of multicellular organisms.

Authors:  Michael Zasloff
Journal:  Nature       Date:  2002-01-24       Impact factor: 49.962

Review 2.  Tryptophan- and arginine-rich antimicrobial peptides: structures and mechanisms of action.

Authors:  David I Chan; Elmar J Prenner; Hans J Vogel
Journal:  Biochim Biophys Acta       Date:  2006-04-21

Review 3.  The mononuclear phagocyte system.

Authors:  David A Hume
Journal:  Curr Opin Immunol       Date:  2005-12-09       Impact factor: 7.486

4.  Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation.

Authors:  Frank A W Verreck; Tjitske de Boer; Dennis M L Langenberg; Linda van der Zanden; Tom H M Ottenhoff
Journal:  J Leukoc Biol       Date:  2005-12-05       Impact factor: 4.962

5.  The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii.

Authors:  Lenie Dijkshoorn; Carlo P J M Brouwer; Sylvia J P Bogaards; Alexandr Nemec; Peterhans J van den Broek; Peter H Nibbering
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

6.  Candidacidal activities of human lactoferrin peptides derived from the N terminus.

Authors:  A Lupetti; A Paulusma-Annema; M M Welling; S Senesi; J T van Dissel; P H Nibbering
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

7.  IL-10-producing macrophages preferentially clear early apoptotic cells.

Authors:  Wei Xu; Anja Roos; Nicole Schlagwein; Andrea M Woltman; Mohamed R Daha; Cees van Kooten
Journal:  Blood       Date:  2006-02-23       Impact factor: 22.113

8.  Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species.

Authors:  Antonella Lupetti; Akke Paulusma-Annema; Mick M Welling; Heleen Dogterom-Ballering; Carlo P J M Brouwer; Sonia Senesi; Jaap T Van Dissel; Peter H Nibbering
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  99mTc-Labeled UBI 29-41 peptide for monitoring the efficacy of antibacterial agents in mice infected with Staphylococcus aureus.

Authors:  Peter H Nibbering; Mick M Welling; Akke Paulusma-Annema; Carlo P J M Brouwer; Antonella Lupetti; Ernest K J Pauwels
Journal:  J Nucl Med       Date:  2004-02       Impact factor: 10.057

10.  Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11).

Authors:  Walter J F M van der Velden; Thijs M P van Iersel; Nicole M A Blijlevens; J Peter Donnelly
Journal:  BMC Med       Date:  2009-09-08       Impact factor: 8.775

View more
  22 in total

Review 1.  Designing antimicrobial peptides: form follows function.

Authors:  Christopher D Fjell; Jan A Hiss; Robert E W Hancock; Gisbert Schneider
Journal:  Nat Rev Drug Discov       Date:  2011-12-16       Impact factor: 84.694

Review 2.  New horizons for host defense peptides and lantibiotics.

Authors:  Michael John Dawson; Richard W Scott
Journal:  Curr Opin Pharmacol       Date:  2012-07-07       Impact factor: 5.547

Review 3.  The immune response and antibacterial therapy.

Authors:  Olachi Anuforom; Graham R Wallace; Laura V Piddock
Journal:  Med Microbiol Immunol       Date:  2014-09-05       Impact factor: 3.402

Review 4.  Pharmacological Targeting of the Host-Pathogen Interaction: Alternatives to Classical Antibiotics to Combat Drug-Resistant Superbugs.

Authors:  Jason Munguia; Victor Nizet
Journal:  Trends Pharmacol Sci       Date:  2017-03-08       Impact factor: 14.819

5.  A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy.

Authors:  John R North; Shunsuke Takenaka; Annett Rozek; Agnieszka Kielczewska; Steven Opal; Lisa A Morici; B Brett Finlay; Christopher J Schaber; Richard Straube; Oreola Donini
Journal:  J Biotechnol       Date:  2016-03-23       Impact factor: 3.307

6.  Antibacterial mechanism of action of arylamide foldamers.

Authors:  Bruk Mensa; Yong Ho Kim; Sungwook Choi; Richard Scott; Gregory A Caputo; William F DeGrado
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

Review 7.  Multifunctional cationic host defence peptides and their clinical applications.

Authors:  Amy T Y Yeung; Shaan L Gellatly; Robert E W Hancock
Journal:  Cell Mol Life Sci       Date:  2011-05-15       Impact factor: 9.207

Review 8.  Antimicrobial peptides and peptidomimetics - potent therapeutic allies for staphylococcal infections.

Authors:  Haroon Mohammad; Shankar Thangamani; Mohamed N Seleem
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

9.  The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis.

Authors:  Praveen Papareddy; Martina Kalle; Ole E Sørensen; Martin Malmsten; Matthias Mörgelin; Artur Schmidtchen
Journal:  PLoS Pathog       Date:  2013-12-05       Impact factor: 6.823

10.  Antimicrobial lactoferrin peptides: the hidden players in the protective function of a multifunctional protein.

Authors:  Mau Sinha; Sanket Kaushik; Punit Kaur; Sujata Sharma; Tej P Singh
Journal:  Int J Pept       Date:  2013-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.